MedTrace Logo

An Investigational Study to Evaluate Experimental Medication BMS-986224 in Renally Impaired Participants

NCT03634969 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2020-02-25

No results posted yet for this study

Summary

The purpose of this study is to investigate the experimental medication BMS-986224 in participants with varying levels of renal function.

Conditions

  • Cardiac Failure
  • Myocardial Failure

Interventions

DRUG

BMS-986224

Specified dose on specified days

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-08-14
Primary Completion
2019-04-30
Completion
2019-04-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03634969 on ClinicalTrials.gov